TSE:MDNA Medicenna Therapeutics (MDNA) Stock Price, News & Analysis → Collect 10%+ Dividends from AI's Explosive Growth? (From The Oxford Club) (Ad) Free MDNA Stock Alerts C$2.11 -0.17 (-7.46%) (As of 06/14/2024 ET) Add Compare Share Share Today's RangeC$2.08▼C$2.2950-Day RangeC$1.50▼C$2.8552-Week RangeC$0.22▼C$2.98Volume224,237 shsAverage Volume133,460 shsMarket CapitalizationC$157.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get Medicenna Therapeutics alerts: Email Address Ad The Oxford ClubCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having to buy a single stock?Click here now to claim your FREE copy of Marc's AI playbook. About Medicenna Therapeutics Stock (TSE:MDNA)Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.Read More MDNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDNA Stock News HeadlinesMay 28, 2024 | investing.comMedicenna (MDNA) Earnings Dates & ReportsMay 22, 2024 | finance.yahoo.comMedicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation ForumMay 13, 2024 | finance.yahoo.comMedicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program CommitteeMay 13, 2024 | finance.yahoo.comMedicenna Provides Update on its Presentations at the 2024 ASCO Annual MeetingMay 7, 2024 | seekingalpha.comNew Buy, Medicenna: Superkine Platform In OncologyApril 26, 2024 | ca.finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - MDNAApril 26, 2024 | finance.yahoo.comMedicenna Therapeutics Announces CA$20 Million Investment from RA Capital ManagementApril 9, 2024 | finance.yahoo.comMedicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)April 9, 2024 | finance.yahoo.comMedicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)March 27, 2024 | theglobeandmail.comMedicenna Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (MDNA)March 6, 2024 | finance.yahoo.comMedicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual MeetingFebruary 13, 2024 | finance.yahoo.comMedicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid TumorsJanuary 9, 2024 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with PembrolizumabJanuary 9, 2024 | finance.yahoo.comMedicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with PembrolizumabNovember 20, 2023 | finance.yahoo.comAll You Need to Know About Medicenna Therapeutics Corp. (MDNAF) Rating Upgrade to BuyNovember 14, 2023 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational HighlightsNovember 9, 2023 | finance.yahoo.comMedicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual MeetingOctober 24, 2023 | tmcnet.comMedicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)October 24, 2023 | finance.yahoo.comMedicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)October 10, 2023 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerOctober 5, 2023 | nasdaq.comMedicenna Therapeutics (MDNA) Price Target Increased by 34.63% to 3.93October 3, 2023 | finance.yahoo.comMedicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and ImmunotherapySeptember 29, 2023 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Announces Results of Annual and Special Meeting of ShareholdersSeptember 28, 2023 | finance.yahoo.comMedicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and ImmunotherapySeptember 26, 2023 | finance.yahoo.comIs Medicenna Therapeutics (TSE:MDNA) In A Good Position To Invest In Growth?See More Headlines Receive MDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/15/2024Next Earnings (Estimated)6/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:MDNA CUSIPN/A CIKN/A Webwww.medicenna.com Phone+1-403-6807898FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-15,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.47% Return on Assets-34.57% Debt Debt-to-Equity Ratio0.06 Current Ratio5.00 Quick Ratio4.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$1.84 per share Price / Cash Flow1.15 Book ValueC$0.27 per share Price / Book7.81Miscellaneous Outstanding Shares74,780,000Free FloatN/AMarket CapC$157.79 million OptionableNot Optionable Beta1.29 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Fahar Merchant Ph.D. (Age 67)Founder, Chairman, President & CEO Comp: $454.37kMs. Rosemina Merchant B.Sc. (Age 67)M.E.Sc, Founder & Chief Development Officer Comp: $364.46kMr. David Hyman CA (Age 51)CBV, Chief Financial Officer Dr. Samuel R. Denmeade M.D.Scientific AdvisorKey CompetitorsProMetic Life SciencesTSE:PLIFennec PharmaceuticalsTSE:FRXVIVO CannabisCVE:ABCNEmblemCVE:EMCBriaCell TherapeuticsCVE:BCTView All Competitors MDNA Stock Analysis - Frequently Asked Questions How have MDNA shares performed in 2024? Medicenna Therapeutics' stock was trading at C$0.42 at the start of the year. Since then, MDNA stock has increased by 402.4% and is now trading at C$2.11. View the best growth stocks for 2024 here. When is Medicenna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 25th 2024. View our MDNA earnings forecast. What other stocks do shareholders of Medicenna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include OPKO Health (OPK), AbbVie (ABBV), Livongo Health (LVGO), Aptose Biosciences (APTO), Birchcliff Energy (BIR), CVS Health (CVS), Freehold Royalties (FRU), Fastly (FSLY) and Inovio Pharmaceuticals (INO). How do I buy shares of Medicenna Therapeutics? Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:MDNA) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicenna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.